Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 98 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Carcinoma
Interventions
Ultrasonsgraphy, Perflutren Lipid Microcpheres, Contrast - Enhanced Ultrasound
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Prostatic Neoplasm
Interventions
Perflutren Lipid Microsphere Intravenous Suspension
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Microvascular Flow Assessment Repeatability Study: The MARS Study

NCT01242020
Conditions
Obesity
Interventions
Perflutren Lipid Microsphere Injectable Suspension
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Kidney Neoplasms, Liver Neoplasms
Interventions
contrast agent perflutren lipid, Ultrasound Imaging
Drug · Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Echocardiography
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Soft Tissue Sarcoma
Interventions
Definity, Contrast-Enhanced Ultrasound
Drug · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Thyroid Nodules
Interventions
Definity contrast agent
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Breast Cancer
Interventions
Definity
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Pituitary Adenoma, Cushing Disease
Interventions
Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Inflammatory Bowel Disease
Interventions
Definity
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Liver Diseases, Portal Hypertension
Interventions
SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Endoleaks
Interventions
Definity
Drug
Lead sponsor
E. Peden, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Houston, Texas
Completed Phase 1 Interventional Results available

Regadenoson R-T Perfusion Imaging Trial

NCT00837369
Conditions
Coronary Artery Disease, Myocardial Perfusion Abnormalities
Interventions
Regadenoson
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
30 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Conditions
Ocular Melanoma
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Signs and Symptoms
Interventions
Acoustic Angiography, Definity
Device · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Cystic Fibrosis, Ventilatory Defect
Interventions
19F MRI
Combination Product
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality
Interventions
Optison
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
9 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Augusta, Georgia + 5 more
Conditions
Cardiac Catheterization, Blood Pressure, Heart Ventricles, Echocardiography, Heart Failure
Interventions
Definity
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lymphedema Arm
Interventions
Lumason, Optison, Definity
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Signs and Symptoms
Interventions
Acoustic Angiography
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Predictors of Aortic Aneurysm Growth and Rupture

NCT02022436
Conditions
Abdominal Aortic Aneurysm
Interventions
Contrast Ultrasound
Drug
Lead sponsor
Rabih A. Chaer
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Recruiting No phase listed Observational Accepts healthy volunteers

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

NCT06066723
Conditions
Cystic Fibrosis in Children
Interventions
19F MRI
Combination Product
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Coronary Artery Disease, Diabetes Mellitus Type 2
Interventions
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota